Acquire & License Dossiers
We source high-value pharmaceutical developments from top U.S., EU, and global R&D companies — products selected for genuine commercial opportunity in North America.
Pharmaceutical In-Licensing · Est. 2006
The bridge between global pharma R&D and the U.S. market.
GPP acquires and licenses high-value pharmaceutical dossiers from leading R&D companies worldwide — and partners them with our network of world-class U.S. pharmaceutical businesses.
2006
Founded by Rob Camerer
89
Countries of licensing experience
$500M+
Global investment raised by GPP
$B+
Partner revenues, products signed
What We Do
From dossier to the American shelf.
For nearly two decades, GPP has connected the world's best pharmaceutical science with the companies that bring it to U.S. and Canadian patients.
Partner with U.S. Businesses
Our established network of world-class U.S. pharmaceutical customers gives every licensed product a clear commercial path — the right partner, structured the right way.
Grow Partner Portfolios
We continually expand our R&D partners' product portfolios and our commercial customer base — creating significant, durable business on both sides of the Atlantic.
Focus Areas
Beyond generics — and still growing.
GPP's roots are in generic pharma licensing. Over the past six years our scope has expanded dramatically across the development spectrum.
Generic Pharmaceuticals
Our original focus — bringing proven, high-quality generic dossiers from global R&D companies into the U.S. and Canadian markets.
Specialty Pharma
Differentiated specialty products serving focused patient populations and high-value therapeutic niches.
505(b)(2) / EU Hybrids
Value-added developments that build on established molecules — faster pathways with real clinical and commercial differentiation.
Innovative Developments
Novel drug developments from R&D partners with the science to compete on the world's largest pharmaceutical stage.
Drug / Device Combinations
Combination products that pair formulation science with delivery technology for better outcomes and stronger positioning.
Biologicals
Our newest frontier — extending GPP's licensing model into biologics and biosimilars for the markets of the future.
How It Works
A proven path to the U.S. market.
Identify
We evaluate dossiers and pipelines from global R&D companies, selecting products with genuine U.S. commercial opportunity.
Structure
We craft licensing and acquisition terms that work for the developer, the commercial partner, and the market.
Partner
We place each product with the right company in our U.S. network — matched on capability, channel, and commitment.
Commercialize
We support both sides through registration, launch, and growth — building revenue that compounds for years.
Let's Talk
Contact GPP
Have a dossier ready for the U.S. market?
Whether you're an R&D company seeking a U.S. pathway or an American business looking for your next product, the conversation starts here.